申请人:Takeda Pharmaceutical Company Limited
公开号:US20220289679A1
公开(公告)日:2022-09-15
The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as described in the description, or a salt thereof.
本发明提供一种具有葡糖鞘氨醇合成酶抑制作用的化合物,预计可用作预防或治疗溶酶体贮积病(如高氏病、法布里病、GM1神经节苷脂沉积症、GM2激活因子缺乏症、泰-萨克斯病、桑德霍夫病)、神经退行性疾病(如帕金森病、Lewy体痴呆、多系统萎缩)等的药物。本发明涉及一种由式(I)表示的化合物,其中每个符号如描述中所述,或其盐。